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In 2004, an estimated 1.4 million
adults were newly diagnosed
with diabetes, which represents a
nearly 54% increase since 1997.1
It has been predicted that within
approximately 50 years the
prevalence of diabetes in the
United States will increase by
165% to approximately 29 million.2 Therefore, health care professionals must continue to educate themselves and others about
the prevention and management
of diabetes.
Both the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE) promote
the early diagnosis and intensive
management of diabetes.3,4 The
intensive management of diabetes is described as long-term
maintenance of near normal glucose concentrations and also includes the optimization of other
related health conditions (eg,
dyslipidemia, hypertension, obesity). The goals for intensive
management of diabetes have
been proven to decrease diabetes-associated complications and
reduce mortality.4 In order for
patients with diabetes to achieve
these goals, ADA recommends

that pre-prandial plasma glucose
be maintained between 90 and 130
mg/dL, peak postprandial plasma
glucose remain below 180 mg/dL,
and hemoglobin A1c (HbA1c)
remain below 7%.3 AACE recommends that diabetic patients
follow more strict criteria to include pre-prandial glucose less
than 110 mg/dL, postprandial glucose less than 140 mg/dL, and a
HbA1c less than or equal to
6.5%.4
It is important to remember that
these recommendations are guidelines and that treatment should be
individualized to each patient in
order to optimize management
while reducing the occurrence of
side effects and adverse reactions.
ADA also recommends a goal
blood pressure less than 130/80
mmHg, LDL less than 100 mg/dL,
HDL greater than 40 mg/dL, and
triglycerides less than 150 mg/dL
for all diabetes patients.3
The foundation of diabetes treatment begins with proper diet, exercise, and education of the newly
diagnosed patients.2,3 Although
type 1 diabetes therapy will require the administration of insulin
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upon diagnosis these principles
remain critical to their care. On
the other hand, patients with type
2 diabetes may begin their treatment and reach target goals
strictly with diet and exercise. If
significant improvement is not
seen or maintained with nonpharmacological therapy, then treatment with oral antidiabetic agents,
insulin, or combination of agents
can be initiated. There are several
classes of antidiabetic agents that
have unique mechanisms of action; therefore, treatment can be
tailored to the individual patient’s
needs (Table 1).
Treatment typically begins by
adding 1 oral agent to lifestyle
modifications. The selection of
this agent depends on the clinical
picture of disease (ie, insulin resistance versus insulin deficiency)
in each individual patient.
Patients with insulin resistance
may be characterized by being
obese and having elevated fasting
blood glucose concentrations.
Their diabetes is typically associated with hypertension and hyperlipidemia. Metformin or a thiazolidinedione would be the optimal initial choice for these patients, since these agents act by
sensitizing tissue to the insulin
that is present and by decreasing
the production of glucose by the
liver.4,5 In comparison, patients
who are leaner and have elevated
post-prandial blood glucose are
more likely to have insulin deficiency.3-5 For these patients, selecting agents that increase the
release of insulin from the remaining functioning beta cells (eg, sulfonylurea, nonsulfonylurea secretagouge) would be optimal.5 Addi-
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tionally, an alpha glucosidase
inhibitor that acts by delaying
the absorption of carbohydrates
from the gastrointestinal tract
would also be beneficial in these
patients.5
If significant improvement is not
seen with the maximum tolerated dose after 3 months, a second agent with a different
mechanism of action can be
added.4,5 Combination of oral
agents is very common and
many are available commercially
as combination products. If targets are still not reached within 3
months the addition of insulin
can be considered.4,5 If the patient is within 1 percentage point
of reaching their goal, another
option would be a combination
of 3 agents (eg, metformin + sulfonylurea + thiazolidinedione or
metformin + sulfonylurea + exenatide).3-5
ADA guidelines do not include
the alpha-glucosidase inhibitors
(ie, acarbose, miglitol), nonsulfonylurea secretagogues
(ie,
repaglinide, nateglinide), or
newer antidiabetic agents (ie,
inhaled insulin, pramilintide, exenatide). These agents are generally less effective in lowering
HbA1c, have limited clinical
data, or are more expensive than
other agents. Therefore, these
agents should be considered in
patients who are close to their
goal HbA1c and continue to
have postprandial hyperglycemia.
Pramlintide (Symlin®) is an analogue of the exogenous peptide
amylin, which is a neurohormone that is secreted from beta

cells along with insulin in response to meals. The release of
amylin results in a reduction in
food intake, slows gastric emptying, and decreases glucagon release resulting in the reduction of
postprandial serum glucose concentrations.8,9
Pramlintide, indicated for use with
meal-time insulin for uncontrolled
type 1 and type 2 diabetes, is administered as a subcutaneous injection immediately prior to meals
(Table 2). The administration of
pramlinitide with mealtime insulin
has been shown to approximately
reduce hemoglobin A1c by 0.1 to
0.6% in type 1 and 2 diabetes and
also reduce 2-hour postprandial
glucose concentrations by 3.6 to
4.8 mmol/L.9 Weight reduction is
another beneficial effect seen with
the use of pramlinitide compared
with the weight gain typically
seen with insulin therapy; however, long term data are lacking.9
The most common adverse effects
are hypoglycemia and nausea. In
order to reduce risk of hypoglycemia, close monitoring of blood
glucose concentrations with initiation of therapy is recommended
along with a 50% empiric dose
reduction in short-acting premeal
insulin.8,9
The 2 newest classes of antidiabetic agents are the incretin mimetics and dipeptidyl peptidase
IV inhibitors. These agents work
through effects on the incretin gut
hormone, glucagon-like-peptide-1
(GLP-1). This hormone is secreted
within minutes after the ingestion
of food and results in the stimulation of glucose-dependent insulin.
It is then quickly degraded by the
enzyme dipeptidyl peptidase IV.10
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Patients with type 2 diabetes demonstrate deficiencies in the secretion of incretin hormones. The
incretin mimetics act to replace
the insufficient endogenous secretion of GLP-1, whereas the dipeptidyl peptidase IV inhibitors act to
limit the breakdown of endogenous GLP-1. Therefore, both
agents act to increase the amount
of GLP-1 that is available in the
body.10 Additionally, GLP-1 enhances glucose-dependent insulin
secretion, suppresses glucagon
secretion, suppresses appetite,
regulates gastric emptying, and
promotes proliferation and neogenesis of beta cells.10
Exenatide (Byetta®) is an incretin
mimetic indicated for treatment of
type 2 diabetes in patients who
have not met their goals with metformin, a sulfonylurea, or combination of a sulfonylurea and metformin.10,11 Exenatide is administered subcutaneously, twice daily
(Table 2).11 The expected HbA1c
reduction is lower than other
agents at approximately 0.5 to 1%.
Common adverse effects and contraindications are listed in Table
1.10,11 Currently, exenatide is not
approved for the treatment of patients with type 2 diabetes that
have failed other therapies or
those with type 1 diabetes.
Sitagliptin (Januvia®), is a dipeptidyl peptidase IV inhibitor that is
approved for the treatment of type
2 diabetes as monotherapy or in
the combination with metformin
or a thiazolidinedione.10-13 Dosing
is listed in Table 2, and dose reductions are recommended for
those patients with moderate renal
impairment.12
The expected
HbA1c reduction is lower than
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other agents at approximately
0.6 to 0.8%. To date, serious
adverse effects have not been
reported with sitagliptin; however, minimal hypoglycemia and
weight gain have been noted in
clinical trails.10, 13
The latest development in insulin technology is the recent approval of Exubera®, the first inhaled human insulin.6 This new
insulin is indicated for the treatment type 1 and type 2 diabetes.6
It has been shown to have a
more rapid onset with a similar
duration of action compared
with regular human insulin.6 Adverse effects associated with the
use of inhaled insulin include
hypoglycemia and weight gain;
however, these effects were
comparable with those seen with
subcutaneous regular insulin.6,7
It is important to note that the
dosing is different compared
with injectable insulin products
(Table 2). The initial dose of inhaled insulin is 0.05 mg/kg administered just prior to meals.7
Exubera® is available as 1-mg
and 3-mg unit-dose blister cartridges with 1 mg being equivalent to 3 units of regular insulin
and 3 mg being equivalent to 8
units of regular insulin.7 Due to
the differences in conversion to
units, three 1-mg blister cartridges is not equivalent to one
3-mg blister cartridge. Therefore, it is important to educate
patients about their difference if
they require both 1- and 3-mg
cartridges.
The incidence of type 2 diabetes
continues to grow. Aggressive
therapy is required to rapidly

achieve and maintain glycemic
control. The recent guidelines
from ADA emphasize these principles and will assist the clinician
in achieving the goals. With the
development of new agents possessing various mechanisms of
action, a population of diabetes
patients that were previously uncontrolled has a better chance of
achieving the goal of tight glucose
control.
References available upon request.

Did You Know...
Amgen recently informed oncology health care practitioners that
results from a large, multicenter,
study showed that darbepoetin
alfa (Aranesp®) was ineffective in
reducing red blood cell (RBC)
transfusions in patients with cancer who have anemia that is not
due to concurrent chemotherapy.
Additionally, this study
showed higher mortality in patients receiving darbepoetin.
In the study, darbepoetin alfa was
compared with placebo in patients
with active malignant disease not
receiving or not expected to receive chemotherapy or radiation
therapy. This study was designed
to establish the effectiveness of
darbepoetin alfa in this new indication but failed to meet its primary endpoint of reducing RBC
transfusions in the darbepoetin
group. This study was not optimal
in design to establish the effect on
survival, a safety endpoint; however, more deaths occurred in the
Aranesp treatment group when
compared with the placebo group.
This manufacturer-sponsored
study was a Phase 3, double-blind,
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randomized, placebo-controlled
study, monitored by an independent Data Safety Monitoring
Board. Patients received treatment for 16 weeks, and additional
safety and effectiveness data will
be obtained from a 16-week extension study in which randomized treatment was continued. Follow up for survival will continue
on patients for a minimum of 2
years.
A total of 989 patients with hemoglobin (Hgb) less than or equal to
11 g/dL, with active cancer, and
who were not receiving myelosuppressive chemotherapy or radiotherapy were enrolled. Approximately 60% of patients enrolled
had advanced (stage IV) disease. The target Hgb was
12 g/dL.
The final analysis of the initial 16week treatment period did not
show a statistically significant effect on the primary efficacy endpoint (Hazard ratio 0.89; 95% CI:
0.65 to 1.22), with an incidence of
RBC transfusions of 24% in the
placebo group compared with
18% in the Aranesp group
(p=0.15).
In the 16-week treatment phase of
the study, more deaths were reported in the darbepoetin group
(26%, n=136/515) than the placebo group (20%, n=94/470).
With median survival follow-up
of 4.3 months the absolute number
of deaths was greater in the darbepoetin group (46%, n=216/470)
and compared with the placebo
group (49%, n=250/515; Hazard
Ratio 1.25; 95% CI: 1.04 to 1.51).
Details of this study will be presented and published in a peer-
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reviewed setting as soon as possible.

with appropriate dosing due to the
formulary changes.

Darbepoetin is not approved for
use in this population. Aranesp
is approved for the treatment of
patients with anemia, which is
caused by chemotherapy treatment of their malignant disease,
rather than the underlying malignant disease itself.

Deletions:
Effective February 15, 2007
Atropine 0.5% ophthalmic
solution

Formulary Update
The Pharmacy and Therapeutics Committee recently approved the actions listed below.
Additions with Restriction:
Effective February 15, 2007
Varicella virus vaccine
(Zostavax®)
Single-dose vial
Prescribing will be restricted to
patients in the outpatient clinics.
Conivaptan (Vaprisol®)
4-mL ampule (20 mg)
Prescribing will be restricted to
euvolemic patients (ie, syndrome
of inappropriate antidiuretic hormone [SIADH]) in an ICU setting who have failed fluid restriction and/or 3% sodium chloride infusions.
Restriction Removed:
**Effective March 15, 2007**
Meropenem (Merrem®)
The formulary restriction will be
removed with the deletion of
imipenem/cilastatin.
Automatic Therapeutic Substitution (ATS) Protocol
**Effective March 15, 2007**
An ATS for meropenem has
been developed by the Antiinfective Subcommittee to assist

**Effective March 15, 2007**
Imipenem/cilastatin (Primaxin®)
Line extension:
Effective February 15, 2 007
Vitamin D emulsion
(Bio-D-Mulsion® Forte)
2000-unit/drop emulsion

Med•U•Way to
Focus on Macular
Degeneration
The next MED•U•WAY
Conference will focus on macular
degeneration. The program will be
held on Thursday, February 18,
2006, at 12:00 PM, in 2 West
Amphitheater.
The featured speakers will be
Esther Bowie, MD, Storm Eye
Institute,
Patrick Kelty, MD,
Resident, Third-Year Resident,
Ophthalmology, and Jim Oates,
MD, Division of Rheumatology
and Immunology.
Attendees will receive 1 credit
hour of continuing education, and
lunch is provided.
MED•U•WAY is sponsored by
the Pharmacy and Therapeutics
Committee.
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Table 1. Available Medications for the Treatment of Diabetes
Mechanism of
Medication Class
Advantages
Action
Sulfonylureas
Stimulates insulin
▪ Convenient daily dosing
▪ Glyburide (DiaBeta®, Micronase®) secretion from func▪ Decreases microvascular risk
tioning beta cells
▪ Micronized glyburide (Glynase®)*
▪ Glipizide (Gluctrol®, Gluctrol XL®)
▪ Glimepiride (Amaryl®)*
Nonsulfonylurea Secretagogues
Stimulates insulin
▪ Targets postprandial
secretion from func▪ Repaglinide (Prandin®)*
glycemic control
®
tioning
beta
cells
▪ Nateglinide (Starlix )*
▪ Less hypoglycemia and
weight gain than with
sulfonylureas
Biguanides
▪ Metformin (Glucophage®)
▪ Metformin extended release
(Glucophage XR®)*

Thiazolidinediones
▪ Rosiglitazone (Avandia®)
▪ Pioglitazone (Actos®)

Reduces hepatic glucose production and
enhances peripheral
glucose uptake

Increases tissue sensitivity to insulin and
reduces hepatic glucose production

Alpha-glycosidase Inhibitors
▪ Acarbose (Precose®)*
▪ Miglitol (Glyset®)*

Delays absorption of
carbohydrates from
GI tract

Incretin Mimetic
▪ Exenatide (Byetta®)*

Increase insulin synthesis and release by
activating GLP-1 receptors, suppresses
glucagon secretion,
slows gastric emptying and regulates
growth of beta cells
Suppresses postprandial glucagon secretion, slows carbohydrate absorption

Amylin Analogues
▪ Pramlinitide (Symlin®)*

Dipeptidyl Peptidase IV Inhibitors
▪ Sitagliptin (Januvia®)*

Inhibits breakdown of
GLP-1 and prolongs
GLP-1 activity

▪ Less risk of weight gain and
potential weight loss

▪ Less risk of hypoglycemia
▪ Decreases microvascular and
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪

macrovascular risk
Decreases LDL and TG
Increased fibrinolysis
Less risk of hypoglycemia
Possible preservation of beta
cell function
Convenient daily dosing
Decreases TG; Increase HDL
Increases fibrinolysis
Decreases blood pressure
Targets PPG
Less risk of hypoglycemia
Less risk of weight gain
Decreases triglycerides
Additional reduction in
HbA1c and PPG
Promotes proliferation and
neogenesis of beta cells
May promote weight loss

Disadvantages
▪ AE: hypoglycemia, weight
gain

▪ TID dosing
▪ AE: hypoglycemia, weight
gain

▪ Cannot be combined
with sulfonylurea
▪ AE: lactic acidosis and GI
effects
▪ CI: renal impairment, hepatic dysfunction, CHF,
metabolic acidosis, dehydration, alcoholism, radio
contrast studies

▪ AE: weight gain, edema
▪ Required LFT monitoring
▪ Avoid in hepatic impairment and CHF

▪ Cost
▪ AE: GI effects
▪ TID dosing
▪ Subcutaneous injection
▪ Must be refrigerated
▪ AE: hypoglycemia,
GI effects

▪ CI: severe GI disease,
severe renal impairment

▪ Weight loss
▪ Decreases insulin use
▪ Modest decrease in HbA1c
and PPG

▪ Additional reduction in
HbA1c and PPG

▪ Once daily dosing
▪ Promotes proliferation and
neogenesis of beta cells

*Nonformulary agents; CI = contraindications; AE = common adverse effects; GI = gastrointestinal; HbA1c = hemoglobin A1c; PPG = post prandial glucose

▪ Subcutaneous injection
▪
▪
▪
▪

with meals
Unable to mix with
insulin
AE: hypoglycemia, nausea
Renal dose adjustment
Patient cost
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Table 2. Doses and Average Costs of Antidiabetic Agents
Medication

Dose

Average Patient Cost
(30-day supply)+

Glyburide
(DiaBeta®, Micronase®)

1.25 -20 mg daily to twice daily (Max: 20 mg/day)

$11

Micronized glyburide (Glynase®)*

0.75-12 mg daily to twice daily (Max: 12 mg/day)

$19

Immediate release: 5 mg daily to BID
(Max: 40 mg/day)
Extended release: 5 to 10 mg daily
(Max: 20 mg/day)
1 to 4 mg daily (Max: 8 mg daily)

$24

Repaglinide (Prandin®)*

0.5 to 4 mg BID to QID with meals
(Max: 16 mg/day)

$125

Nateglinide (Starlix®)*

60 to 120 mg TID with meals
(Max: 360 mg/day)

$120

Metformin (Glucophage®)
Metformin extended release
(Glucophage XR®)*

Immediate release:1000 to 2550 mg divided BID to
TID (Max: 2550 mg/day)
Extended release: 1000 to 2000 mg daily
(Max: 200 mg/day)

Rosiglitazone (Avandia®)

4 mg daily to BID (Max: 8 mg/day)

Pioglitazone (Actos®)*

15 to 30 mg daily
(Max: 45 mg daily)
50 to 100 mg TID with meals
(Max ≤ 60 kg: 150 mg/day)
(Max > 60 kg: 300 mg/day)
50 to 100 mg TID with meals
(Max: 300 mg/day)

Glipizide
(Glucotrol®, Glucotrol XL®)
Glimepiride (Amaryl®)*

Acarbose (Precose®)*
Miglitol (Glyset®)*
Glyburide/metformin (Glucovance®)*

$4

$7

$80
$82
$139
$181
$81
$74

2.5/500 to 5/500 mg BID (Max: 20 mg/2000 mg)

$70

Glipizide/metformin (Metaglip )*

2.5/500 to 5/500 mg BID (Max: 20 mg/2000 mg)

$63

Pioglitazone/metformin
(Actoplus Met®)*

15/500 to 15/850 mg daily to BID
(Max: 45/2550 mg/day)

$166

Rosiglitazone/metformin (Avandamet®)*

1/500 to 4/1000 mg daily to BID
(Max: 8/2000 mg daily)

$230

Rosiglitazone/glimepiride (Avandaryl®)*

4/1 to 4/2 mg daily (Max: 8/4 mg/day)

$116

Sitagliptin (Januvia®)*

100 mg daily

$120

Exenatide (Byetta®)*

5 to 10 micrograms, SC, BID
(Max: 20 micrograms/day)

$176

Pramlinitide (Symlin®)*

30 to 60 micrograms, SC, with major meals
Type 1 DM: initial dose - 15 to 30 micrograms, increased to 45 to 60 micrograms, as tolerated
Type 2 DM: initial dose - 60 micrograms, increased
to 120 micrograms, as tolerated

$95

®

0.05 mg/kg with meals
Inhaled human insulin
(Exubera®)*

1 mg = 3 units of regular insulin
3 mg = 8 units of regular insulin

*Nonformulary agents; + Cost based on average wholesale price

$180
(Exubera® kit: w/inh chamber)
$134
(Exubera® combination kit:
1 mg & 3 mg, 2 release units)

